Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results

IF 3.7 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International Pub Date : 2025-01-11 DOI:10.1111/bju.16645

Pietro Scilipoti, Mattia Longoni, Mario de Angelis, Paolo Zaurito, Albane Massiet, Daniele Dutto, Francesco Soria, Mario Álvarez-Maestro, Alfredo Aguilera Bazán, Benjamin Pradere, Tobias Klatte, Roberto Contieri, Rodolfo Hurle, Wojciech Krajewski, José Daniel Subiela, Renate Pichler, Aleksandra Szostek, Gautier Marcq, José Luis Rodríguez Elena, Javier Aranda, Paolo Gontero, Morgan Rouprêt, Shahrokh F. Shariat, Andrea Necchi, Francesco Montorsi, Alberto Briganti, Evanguelos Xylinas, Marco Moschini, ,

引用次数: 0

Abstract

To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high-risk and very-high-risk non-muscle-invasive bladder cancer (NMIBC) after previous Bacillus Calmette–Guérin (BCG) treatment.

查看原文本刊更多论文

吉西他滨和多西他赛治疗高危非肌浸润性膀胱癌：EuroGemDoce组结果

在欧洲一组高风险和极高风险非肌浸润性膀胱癌（NMIBC）患者中，经卡介苗（BCG）治疗后，序贯膀胱内注射吉西他滨/多西他赛（Gem/Doce）治疗的肿瘤学疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BJU International 医学-泌尿学与肾脏学

CiteScore

9.10

自引率

4.40%

发文量

262

审稿时长

1 months

期刊介绍： BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles in the field of urology. BJUI employs topical sections, and is in full colour, making it easier to browse or search for something specific.